Article
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.
Blood - 30 Jul 2026
Duployez Nicolas, Joudinaud Romane, Boudry Augustin, Hunault Mathilde, Fenwarth Laurène, Tavernier Emmanuelle, Pautas Cécile, Bertoli Sarah, Tavitian Suzanne, Raffoux Emmanuel, Hospital Marie-Anne, Marchand Tony, Heiblig Maël, Chantepie Sylvain, Carre Martin, Peterlin Pierre, Gallego-Hernanz Maria-Pilar, Guieze Romain, Simand Célestine, Turlure Pascal, Huynh Anne, Lemasle Emilie, Gabellier Ludovic, Lambert Juliette, Suarez Felipe, Chraibi Samy, Sanhes Laurence, Celli-Lebras Karine, Mineur Ariane, Gardin Claude, Ifrah Norbert, Vey Norbert, Peffault De Latour Régis, Rigolot Lucie, Luquet Isabelle, Penther Dominique, Itzykson Raphaël, Delabesse Éric, Hamel Jean-François, De Botton Stéphane, Pigneux Arnaud, Dombret Hervé, Récher Christian, Preudhomme Claude, Dumas Pierre-Yves
Abstract excerpt
ABSTRACT: FLT3 internal tandem duplications (FLT3-ITD) are major genetic events in acute myeloid leukemia (AML). Although the clinical impact of FLT3-ITD "macroclones" (allelic ratio [AR] ≥0.05) is well established, the significance of low-level FLT3-ITD subclones ("microclones") remains uncertain. We conducted a post hoc analysis of 1733 patients with newly diagnosed AML enrolled in the Backbone Intergroup 1...
Topics
Join the communities discussing this publication.